Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 2/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339084 | 0.76 | PTGS1 (0.46) | EDNRAACHECTPS1ABL1 | |
| SCHEMBL30338582 | 0.76 | PTGS1 (0.46) | EDNRAACHECTPS1ABL1 | |
| SCHEMBL6292182 | 0.74 | ROCK2 (0.35) | KDM4EMEN1KMT2A | |
| SCHEMBL19331916 | 0.67 | EDNRA (0.36) | TSHRSCN9AEDNRAACHEKDM4E | |
| SCHEMBL30562266 | 0.65 | EDNRA (0.46) | EDNRAACHEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3432475 | 0.65 | EDNRA (0.46) | EDNRAACHEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4740343 | 0.65 | ACHE (0.44) | TSHREDNRAACHEKDM4EALDH1A1 | |
| SCHEMBL13163233 | 0.63 | TSHR (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL19342460 | 0.62 | ACHE (0.34) | SCN9AEDNRAACHEKDM4ESMN1; SMN2 | |
| SCHEMBL23562355 | 0.62 | EDNRA (0.43) | TSHREDNRAACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | TSHR 4686/4885SCN9A 4173/4885EDNRA 4781/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | TSHR 4686/4885SCN9A 4173/4885EDNRA 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.